Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telithromycin in Acute Exacerbation of Chronic Bronchitis
NCT00288223Phase 4Terminated
- Sponsor
- Sanofi
- Start
- Jan 2006
- Primary completion
- Jan 2007
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of telithromycin in chronic bronchitis (CB), sponsored by Sanofi. Primary endpoints: Percentage of clinical success (cure + improvement) at TOC visit, Clinical success at follow up visit and 1 more. Started Jan 2006; status: terminated.
02
Drugs
telithromycin
03
Conditions
chronic bronchitis (CB)
Beyond the preview
Go deeper on NCT00288223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00288223.